Andreas Kaiser
Berlin, BE 13353, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Journal: European journal of endocrinology
Published: December 05, 2022
Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: May 13, 2022
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 24, 2021
Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women.
Journal: Clinical pharmacology in drug development
Published: July 21, 2020
Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human.
Journal: Basic & clinical pharmacology & toxicology
Published: July 03, 2020
Absorption, distribution, metabolism and excretion of molidustat in healthy participants.
Journal: Basic & clinical pharmacology & toxicology
Published: January 17, 2020
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Journal: European journal of clinical pharmacology
Published: June 14, 2019
Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women.
Journal: Journal of clinical pharmacology
Published: June 26, 2017
Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women .
Journal: International journal of clinical pharmacology and therapeutics
Published: November 15, 2016
Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Journal: Human reproduction (Oxford, England)
Published: August 17, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026